

# Mai Tomiguchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2974452/publications.pdf>

Version: 2024-02-01

16  
papers

291  
citations

1040056

9  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac computed tomography-derived myocardial tissue characterization after anthracycline treatment. <i>ESC Heart Failure</i> , 2022, 9, 1792-1800.	3.1	3
2	Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum. <i>Breast Cancer</i> , 2021, 28, 746-754.	2.9	3
3	Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity. <i>IJC Heart and Vasculature</i> , 2021, 34, 100797.	1.1	8
4	Factors involved in early lenvatinib dose reduction: a retrospective analysis. <i>Medical Oncology</i> , 2018, 35, 19.	2.5	9
5	Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. <i>Molecular Cancer</i> , 2018, 17, 67.	19.2	40
6	Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 353-362.	2.5	20
7	ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study. <i>Cancer Biomarkers</i> , 2018, 22, 345-350.	1.7	5
8	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. <i>Atherosclerosis</i> , 2017, 260, 116-120.	0.8	33
9	Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. <i>Translational Oncology</i> , 2017, 10, 766-771.	3.7	29
10	Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 786.	2.6	13
11	Analysis of <i>ESR1</i> and <i>PIK3CA</i> mutations in plasma cell-free DNA from ER-positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 52142-52155.	1.8	48
12	Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. <i>Cancer Science</i> , 2016, 107, 491-498.	3.9	40
13	Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report. <i>International Cancer Conference Journal</i> , 2016, 5, 202-205.	0.5	3
14	Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer. <i>Surgery Today</i> , 2016, 46, 214-223.	1.5	8
15	C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients. <i>European Journal of Human Genetics</i> , 2015, 23, 949-956.	2.8	25
16	Correlation between clinical tumor stiffness by elastography and response to neoadjuvant chemotherapy in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1061-1061.	1.6	4